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Abstract
The spread of cancer into the central nervous system is a serious problem leading to neurological symptoms and
rapid mortality. The current tools available for detecting the spread of cancer into the cerebrospinal fluid (CSF) are
cytology, neurologic examination, and neuroimaging. All three of these methods can be applied in concert to
reach a diagnosis, but they all suffer from a lack of sensitivity, leading to delays in treatment in many cases. An
overview of research tools in the field of CSF cancer detection reveals a variety of promising technologies that can
be used to answer questions about the biology of metastatic cancer and to develop more powerful clinical
detection methods. Methods currently under investigation include new immunocytochemistry methods and flow
cytometry for the in vitro detection of cells. Additionally, polymerase chain reaction, fluorescence in situ
hybridization, capillary electrophoresis with laser-induced fluorescence, and mass spectrometry using matrix-assisted
laser absorption-deionization time-of-flight and surface-enhanced laser desorption/ionization time-of-flight
techniques are being tested for in vitro assessment of the non-cellular biomarkers in CSF. For in vivo detection of
cancer in the CSF, research techniques include certain quantum dot platforms as well as magnetic iron oxide
nanoparticles. As systemic therapies for cancer improve, the CNS is becoming a more common site of disease
recurrence. This increases the importance of effective detection methods in the CSF, since early intervention can
maximize therapeutic benefit. Furthermore, many cell-based detection methods can be combined with therapeutic
agents to serve multiple medical functions through a common targeting system.
Review
Introduction
The ability to detect and characterize malignant cells in
the CSF derived from primary neural and extraneural
cancers may allow us to answer fundamental questions
about the biology of metastatic spread through identifi-
cation and characterization of the cancer cell popula-
tions capable of infiltrating the CSF. Cancer may reach
the CSF through hematogenous spread, direct extension
from the tumor itself, or by migration along perineural
or perivascular spaces [1,2]. Improved detection of CSF
malignancy is a clinical imperative as well, since current
diagnostic techniques are insensitive, resulting in a delay
in diagnosis until disease-related symptoms are pro-
found and irreversible, and therapeutic options are lim-
ited or non-existent. Cancer cells infiltrating the CSF
can lead to neoplastic meningitis, a rapidly progressive
and fatal condition characterized by serious neurologic
deficits [3]. Across all cancer diagnoses, leptomeningeal
involvement is seen in roughly 5% of patients, and car-
ries a poor prognosis with median survival under 3
months characterized by rapid neurologic decline [3,4].
The biochemical and molecular mechanisms underlying
this process remain unknown. Their elucidation may
dramatically improve our ability to predict, treat, and
even prevent this increasingly frequent and uniformly
fatal complication of cancer. The primary aim of this
review is to describe the state of the field of cancer cell
detection in the CSF with the goal of inspiring transla-
tional scientists to develop the next generation of
clinical detection strategies.
Current clinical techniques
A prior review by Chamberlain and colleagues described
the three primary methods of detecting leptomeningeal
metastasis and the spread of tumor cells into the CSF:
CSF cytology, neurologic examination, and radiographic
imaging of the neuraxis [5]. While all three of these
techniques can be used to diagnose leptomeningeal
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any medium, provided the original work is properly cited.metastases, they all suffer from limitations and generally
only detect the presence of tumor late in the disease
course.
CSF cytology, in which CSF is prepared and examined
under a microscope to look for cells, is currently consid-
ered the gold standard for diagnosis of leptomeningeal
metastasis [5]. While it is highly specific (> 95%), it suf-
fers from a lack of sensitivity (< 50%) [5]. However,
optimum technique including obtaining 10.5 mL or
more of sample, performing a second collection if the
first is negative, taking CSF from as close to the tumor
as possible (when the tumor is visible with neuroima-
ging) and expeditious processing, can maximize the like-
lihood of detecting cells when they are present in the
CSF [6]. In all the studies discussed that compare
another method to cytology, it is important to consider
that proper handling procedures like those above could
improve the diagnostic efficiency of cytology. Therefore,
the methods used to prepare CSF for cytology and other
analyses should be considered for all scientific and clini-
cal investigations involving CSF cells. Even with this
approach, however, false-negative results and delays in
diagnosis are still a major concern given the need to
direct these patients to early aggressive treatment [6,7].
Immunostaining has been used to improve detection,
identify the original tumor type and guide management,
suggesting that better immunostaining and cell labeling
techniques could be used in the clinic as well as for
answering scientific questions about cancer [7,8]. For
instance, in the field of neuro-oncology, there is a hope
that understanding the phenotypic changes (through
surface marker expression and genetic mutations) that
encourage metastasis will reveal new drug targets for
the containment and elimination of cancers. One major
weakness of CSF cytology is that uniform distribution of
cancer cells in the CSF is rarely a safe assumption. For
example, a 1998 study by Chamberlain showed that 14
of the 30 patients with leptomeningeal metastasis tested
were found to have blockages in CSF flow [9]. Further-
more, in 90 taps on 52 patients comparing lumbar and
ventricular shunt taps, there were 12 cases of positive
CSF cytology in lumbar taps with negative shunt taps,
whereas there were only 2 cases with positive shunt taps
and negative lumbar taps [10]. Even when blockages are
not present in the CSF, malignant cells will be found in
greater concentration nearer to regions of the CNS exhi-
biting radiographic or clinical signs due to the diffusion
of cells [6,11]. These latter examples emphasize the
point made earlier that collecting CSF most proximal to
the tumor is likely to be the most informative, an intui-
tive but important point because CSF samples are gen-
erally only withdrawn from one site. Although cytology
is considered the gold standard for detection of neoplas-
tic cells in the CSF, its low sensitivity makes the
interpretation of other measures difficult. When a
method is shown to be more sensitive than CSF cytol-
ogy, it should be noted that it is difficult to distinguish
between false positives and true increases in sensitivity
without a demonstrated association with clinical
outcome.
T h es e c o n ds t a n d a r dm e t h o do fd e t e c t i n gc a n c e ri n
the CSF is by clinical findings including headache, men-
tal status changes, diplopia, weakness, and sensory loss
[1]. This method is challenging because many patients
with CSF spread of neoplastic cells have concomitant
primary tumors, surgeries, and radio- and chemothera-
pies that can confound detection by causing abnormal
findings on neurologic examination. Additionally, tumor
growth sufficient to manifest clinical signs and symp-
toms is often a late finding in the course of CSF spread,
rendering any potential treatments less effective. Finally,
while appropriate treatment may slow or arrest tumor
progression, established neurologic deficits are rarely
reversible. For all these reasons, it is imprudent to wait
for clinical manifestations to appear before initiating
treatment and emphasizes the need for a reliable detec-
tion method.
The third primary means of detecting cancer in the
CSF is through neuroimaging. Among the neuroimaging
modalities, gadolinium-enhanced MRI of the neuraxis is
the method of choice [1]. MRI has the potential to
detect the presence of cancer in the leptomeninges
when cytologies are negative, and is more likely to
detect solid tumor metastases than hematologic metas-
tases to the CSF [12,13]. Gadolinium-enhanced MRI
may be more sensitive than cytology, but its lower speci-
ficity precludes it from replacing cytology as the gold
standard for diagnosis [14]. Also, the clinical use of MRI
to aid diagnosis has not shown any clear survival benefit
[3]. This lack of improvement in survival is probably
due to both the limited spatial resolution of MRI and
the paucity of effective treatments for CSF infiltration of
cancer. While MRI is an important clinical tool for
detecting leptomeningeal metastasis, its limitations high-
light how emerging technologies could fill gaps in the
clinical armamentarium. To maximize the chances of
successfully eliminating cancer in the CSF, it will be
necessary to detect changes at the cellular level rather
than waiting for a macroscopic tumor to emerge.
Emerging research directions
Because the clinically utilized methods for detecting the
presence of cancer cells in the CSF suffer from multiple
limitations, a wide array of alternatives are being devel-
oped to better answer clinical and basic science ques-
tions. Broadly, these efforts focus on both improved
in vitro analysis of CSF and in vivo imaging and spectro-
scopy techniques.
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Immunocytochemistry
As far back as 1984, the use of monoclonal antibodies
like UJ13A for neuroectodermal cells, LE61 for cytokera-
tin, and 2D1 for leucocytes to detect and diagnose
cancer in the CSF, showed advantages over conventional
cytology [15]. Combined with the vast array of antibo-
dies now available commercially, effective targeting of
metastatic and primary CNS cancer cells in the CSF
should already be possible for most tumor types [16-18].
Promising antibodies and targeting peptides abound,
with new discoveries occurring rapidly. While not
intended to be exhaustive, Table 1 shows a few exam-
ples of promising ligands for immunocytochemical
applications. The vast majority of these targeting ligands
have not been evaluated for their utility in the CSF, so
much work remains to establish them as viable detec-
tion tools for leptomeningeal metastasis. In the blood,
there is an increasing interest in identifying circulating
tumor cells (CTCs) using antibody and molecule tag-
ging. These methods, including the FDA-approved Cell-
Search technology, should be investigated in the CSF,
particularly in primary CNS tumors where the CSF may
be seeded before the blood [19,20].
The arrival of quantum dots coated for biomedical
applications using polymer coating, lipid encapsulation,
or ligand exchange provides an ideal fluorescent tag for
identifying cancer cells in vitro [21-23]. Organic fluoro-
phores such as fluoresceins and rhodamines are limited
by low photostability, narrow absorption and emission
spectra, and comparatively low quantum yields [24]. In
contrast, quantum dots are photostable, have broad
absorption and narrow emission spectra, and high quan-
tum yields. Quantum dots are also preferable to conven-
tional fluorophores for cancer cell detection because
they have also been shown to specifically label cells and
subcellular targets such as breast-derived cancer cells
when combined with streptavidin/biotin binding to
HER2 [22]. Outside the CSF, HER2-targeted quantum
dots have been used to stain tumor specimens, resulting
in a promising quantitative prognostic marker in breast
cancer [25].
Quantum dots are now proving successful at improv-
ing cellular detection using a variety of antibody and
peptide ligands [26]. As new conjugation techniques
such as DNA-bridged conjugation emerge, the efficiency
of attaching targeting ligands is continuing to improve
[27]. When these DNA-bridged quantum dot conjugates
were used in microfluidic detection arrays, quantum
dots that were conjugated to targeting molecules were
four orders of magnitude more sensitive than similar
assays using conventional fluorophores. More impor-
tantly, the detection sensitivity of these agents exceeded
the other methods of quantum dot targeting that they
tested by at least four fold. Therefore, emerging technol-
ogy continues to improve the detecting ability of quan-
tum dot-based assays.
Flow Cytometry
Another promising method for the detection of cancer
cells in the CSF is flow cytometry. This has been
attempted mostly for hematologic tumors (leukemias
and lymphomas) and has shown promise as a comple-
mentary method to cytology [28]. In work by Nuckel
and colleagues for example, flow cytometry in patients
with hematological malignancy identified 12 patients
that had detectable cells by both modalities, 3 patients
that had positive cytologies but no abnormal findings on
flow cytometry, and 3 patients that had negative cytolo-
gies but abnormalities on flow cytometry [28]. Another
example showed far more sensitivity: When CSF flow
cytometry was performed with fluorophore tagging of
CD antigens, CNS lymphoma was found in 22% of 51
cases compared to a detection rate of only about 2% for
cytology, a statistically significant difference (P =0 . 0 0 2 ) .
Impressively, flow cytometry required a neoplastic clone
to make up only 0.2% of all CSF lymphocytes in order
to be detected. For comparison, conventional cytology
generally requires 5% tumor cells to find a positive
result. The same study showed higher sensitivity in
relapsed CNS lymphoma, although the sample size was
smaller [29]. One concern with this report was the
extremely low detection rate of leptomeningeal disease
by cytology, suggesting an unusual patient sample, sub-
optimal handling of CSF, or a high number of false posi-
tive results from flow cytometry. An additional benefit
of flow cytometry is that automated methods are avail-
able that allow the rapid acquisition and processing of
diagnostic data, meaning that its use may not lead to
significant time expenditures from the clinicians or
researchers if it is used to supplement conventional
cytology routinely [30]. More recently, a larger study
examining 123 patients with B-cell non-Hodgkin’sl y m -
phoma found that flow cytometric analysis using a 9-
antibody panel detected 27 positive cases (22%) while
Table 1 Selected examples of promising molecular
markers for targeted detection
Disease Marker Source
Glioma IL-13 [76]
Breast Cancer HER2 [22]
Lung Cancer HER2 [77]
Malignant Melanoma 9.2.27 [68]
Genitourinary Tumors (Ovarian) HER2 [77]
Head and Neck Cancers EGFR [78]
Leukemia CD20, CD52 [79]
Lymphoma CD20, CD52 [80]
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[31]. In the Quijano report, only 1 with positive cytology
did not have a corresponding positive flow cytometry
result, and further analysis by immunocytochemistry
ruled out CSF malignancy. Another recent study looked
at clinical outcomes in patients with occult CNS invol-
vement (detectable by flow cytometry but not conven-
t i o n a lc y t o l o g y )c o m p a r e dw i t hp a t i e n t st h a th a d
positive cytologies and no detectable CNS involvement
at all [32]. They found that positive flow cytometry
results alone did not correlate with significantly higher
overall survival, but that they did correlate significantly
with a higher probability of CNS relapse (P = 0.05).
This is encouraging for the future of this technique,
since occult levels of neoplastic cells in the CSF appear
to have a bearing on patient risk. The fact that only
positive cytology showed a significant relationship with
overall survival suggests a continuum of severity in
which increased cell number corresponds to poorer
prognosis and greater need for intervention.
One caveat to the use of flow cytometry on CSF sam-
ples, however, is that the inherently low cell number
and suboptimal cell environment mean that cancer cells
decay rapidly following removal from patient, even
more so when centrifuged repeatedly [7]. Other poten-
tially severe limitations of flow cytometry include a high
rate of false positives at low cell counts (< 25 cells/μL)
and a poor ability to provide differential data (poor dif-
ferentiation between monocytes and eosinophils, and
inability to detect mitoses and neoplastic cells) [33,34].
These considerations limit the current clinical utility of
flow cytometry, but are not necessarily insurmountable
by future developments. Many of the studies in the cur-
rent literature suffer from methodological flaws in the
CSF handling that may be limiting the effectiveness of
the technology for this application. Implementation of
more stringent handling guidelines with respect to
speed of processing, judicious use of centrifugation, use
of a buffer to promote cell viability, and the use of
more robust fluorescent tags may make this technology
more useful than the earlier studies suggest [6,7].
Finally, the widespread use of flow cytometry for the
detection of neoplastic cells in the CSF is limited at this
point by variations in the equipment and methods. The
implementation of standardized protocols across clinical
labs will be necessary before flow cytometry can be
implemented in a routine way alongside conventional
cytology [7].
Polymerase chain reaction/genetic detection
One method that has been used to identify genetic
changes in cancer cells of the CSF is Fluorescence In-Situ
Hybridization (FISH). In one study, 13 of 15 CSF samples
with cells from leptomeningeal cancer patients showed
numerical chromosomal abnormalities compared to no
chromosomal abnormalities in the 10 control samples
[35]. The study was limited by the use of patients that
had already been diagnosed with cytology, meaning that
FISH was in fact less sensitive than cytology. In addition,
7 samples had lysed cells or no cells in this study. While
some of those unusable samples were probably always
devoid of useful cells, the implementation of the handling
guidelines mentioned above may have yielded more use-
able cells for analysis [6]. Specifically, assurance of fast
sample processing would be straightforward to imple-
ment and would increase the likelihood of detecting cells
if they were originally present in the sample. While these
guidelines had not been published at the time of van
Oostenbrugge and colleagues’ investigation, their results
serve to demonstrate how future adherence to handling
guidelines can improve data yield during CSF analyses.
In another notable study, FISH was performed on
tumor samples and CSF cytology slides of 16 patients
with metastatic breast cancer to the leptomeninges to
compare the primary tumor’s HER2 status to that of the
metastatic cells [36]. Using this method, they were able
to show concordance in HER2 amplification between
primary tumor and CSF metastatic cancer cells in all
but 2 of the 16 cases. In the discordant cases, the pri-
mary tumor was positive for HER2 by immunohisto-
chemistry but the CSF cells were negative for HER2
amplification by FISH. Because the HER2 receptor can
be targeted for detection and therapy, this information
c o u l db ea p p l i e dc l i n i c a l l y[ 3 6 ] .I ts h o u l db en o t e dt h a t
FISH is being used to detect chromosomal abnormal-
ities, and would therefore be unable to distinguish
between a malignant change and an increase in copy
number unrelated to malignancy. Therefore, a genetic
aberration would have to be strongly associated with
malignancy for this technique to be useful. Although its
sensitivity may preclude its use as a front-line screening
tool, the existing literature does suggest that it could
mature into a useful tool for guiding clinical decisions.
Another approach to improving the sensitivity of cell
detection is to use polymerase chain reaction (PCR)
methods to amplify DNA specific for cancer cells. One
example is the amplification of IgH rearrangements in
the CSF of patients with CNS lymphomas [37]. More
commonly, reverse-transcription polymerase chain reac-
tion (RT-PCR) is being investigated as a method for
assaying the RNA found in CSF. It offers the advantage
of amplifying small amounts of RNA into a much larger
sample of cDNA; thus only a few neoplastic cells are
needed in the CSF. Perhaps the biggest limitation of
RT-PCR, however, is the need to have the appropriate
primers for the type of RNA being assayed. This could
limit the utility of this approach as a screening tool in
cancers with heterogenous changes in RNA expression.
Despite these concerns, RT-PCR has been used
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variety of primary sources of cancer. For CNS involve-
ment of lymphoma, RT-PCR using probes for clonal
immunoglobulin gene rearrangements demonstrated
positive amplifications in 5 of 13 CSF specimens that
were considered negative for malignancy by cytology
and 5 of 7 specimens that were only considered suspi-
cious for lymphoma by conventional cytology [38].
However, only 2 of the 4 specimens with positive cytol-
ogy had positive RT-PCR amplifications. In malignant
melanoma, RT-PCR of CSF using primers for MART-1,
MAGE-3 and tyrosinase (all known melanoma markers)
were positive for at least one of the markers in 12
patients (vs. 1 positive cytology) of the 37 patients
tested, and correlated significantly with development of
CNS metastasis at 3 months [39]. More recently, RT-
PCR for human mammoglobin has been shown to have
greater sensitivity than cytology (can detect 1 malignant
cell in 10^6 normal cells) and has been successfully
used to diagnose leptomeningeal metastasis in a breast
cancer patient [40]. For leptomeningeal involvement of
leukemias and lymphomas, the technique of single-cell
PCR analysis has potential as a detection method [41].
Able to distinguish between polyclonal reactive and
monoclonal neoplastic increases in B-cells, single-cell
PCR could successfully identify five of the six B-cell
neoplasms as having monoclonal responses.
Noncellular biomarkers
In addition to detecting cancer cells in the CSF through
direct methods, a considerable amount of effort has
focused on indirectly detecting CSF malignancy through
changes in expression patterns of proteins and metabo-
lites in CSF samples. The proteomic/metabolomic
approach could theoretically be more sensitive because
even a few cells could alter the chemical milieu through
disruption of the blood-brain barrier or through direct
shedding of detectable molecules. Examples of CSF bio-
markers for cancer are many. In an early study, carci-
noembryonic antigen (CEA) and the b subunit of
human chorionic gonadotropin (b-HCG) were found to
correlate with leptomeningeal infiltration of the CSF by
carcinoma [42]. Another early study found intrathecal
synthesis of CEA in 89% of meningeal carcinomas and
47% of intraparenchymal carcinomas, suggesting a
future role in detecting at least the cancers that commu-
nicate with the CSF [43]. This limits the use of CEA
(and many CSF proteins) because solid parenchymal
tumors could yield proteins that could be mistaken for
evidence of leptomeningeal disease, resulting in unindi-
cated and potentially harmful intrathecal treatments or
neuraxis radiation. More recently, detection of tumor
markers using a Modular Analytics Serum Work Area
found intrathecal synthesis of CEA, CA125, CA15.3, and
CA19.9 successfully differentiated 17 of 18 patients with
leptomeningeal metastasis from 50 patients with other
neurological diseases [44]. These investigators also
found that VEGF Index was a relatively sensitive (83.3%)
and specific (88.4%) means of detecting leptomeningeal
metastasis. It is important to note that this study did
not use other cancer controls such as solid CNS metas-
tases, so further investigation of these markers would be
necessary before clinical applications could be consid-
ered. Additional studies using High Performance Thin
Layer Chromatography on CSF samples could differenti-
ate medulloblastoma patients and astrocytoma patients
from controls with a P < 0.0002 using ganglioside GD3
[45]. An important consideration in any study of CSF
molecular biomarkers is that disease processes can dis-
rupt the blood-CSF barrier, leading to infiltration of
proteins. Neglecting this can lead to false assumptions
about increased levels of intrathecally produced markers,
so it is important to establish the state of the blood-CSF
barrier using a measure such as albumen quotient [46].
Detection of amino acid profiles in the CSF using
capillary electrophoresis followed by laser-induced fluor-
escence (CE-LIF) detection has been performed in 3
patients with acute lymphoblastic leukemia [47]. This
study revealed significantly different amino acid “finger-
prints” compared to reference values. Despite these pro-
mising findings, the study was limited by its small
sample size and choice of patients who were being trea-
ted with high-dose methotrexate. Follow-up studies
using the same methodology could not be found in the
literature. CE-LIF has since been used for a variety of
other applications ranging from amino acid detection in
Huntington’s disease to the analysis of wine, but it has
been neglected in cancer applications [48]. Since CE-LIF
methods require a small sample volume (50 μL) and a
commercially available instrument, the technique seems
ripe for further use in exploring amino acid biomarkers.
Mass spectrometry using matrix-assisted laser
absorption-deionization time-of-flight (MALDI-TOF)
and surface-enhanced laser desorption/ionization time-
of-flight (SELDI-TOF) techniques has also been
applied to the CSF to detect malignancy. Studies of
MALDI-TOF and SELDI-TOF MS in serum have
demonstrated high sensitivity and specificity for detect-
ing protein biomarkers related to a variety of cancers
including prostate and ovarian, and have been used in
both blood and CSF [49-54]. CSF-focused work has
used SELDI-TOF and MALDI-TOF analysis to identify
promising protein biomarkers in inflammatory and
neoplastic disease [55]. Another investigation used
TOF mass spectrometry in concert with other proteo-
mic methods (Two-dimensional gel electrophoresis and
cleavable isotope-coded affinity tag analysis) to develop
a 21-biomarker panel able to differentiate CSF samples
according to astrocytoma grade [56]. A later study by
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samples and found sensitivity and specificity of 79%
and 76% respectively when differentiating breast cancer
without leptomeningeal metastasis from breast cancer
with it, suggesting no clear benefit to the use of
MALDI-TOF compared to current clinical detection
methods [50]. Despite widespread use, SELDI-TOF and
MALDI-TOF techniques have a variety of limitations.
First of all, both methods are probably missing low-
abundance proteins and peptides because the spectra
of abundant proteins are masking them [57,58]. Fortu-
nately, other proteomic methods are available for
assessing these low-abundance proteins, such as isoba-
ric tags for relative and absolute protein quantification
(iTraq), which have yet to be applied to profiling CSF
malignancy [59]. SELDI-TOF in particular carries
caveats because of its sensitivity to procedural varia-
tion, an unclear relationship between peaks and known
proteins and peptides involved with the disease pro-
cess, and an inability to resolve molecules smaller than
about 100 kDa, which excludes many biologically rele-
vant peptides [60]. Reproducibility issues have been
noted in several cases and limit the usefulness of both
SELDI-TOF and MALDI-TOF without refinements in
protocol [58,61]. The last issue is not a problem for
MALDI-TOF, which can detect molecules as small as
1 kDa. These methods are also not ideal for particu-
larly large molecules, which are better detected with
electrophoresis and immunoblotting [62]. Despite these
considerations, mass spectroscopy methods benefit
from assessment of soluble markers, which are likely
to be more abundant than cancer cells. The emphasis
on molecular detection rather than cellular detection
also lessens concerns associated with using frozen spe-
cimens, which may destroy or alter cells but have
fewer effects on free molecules. MALDI-TOF is likely
to continue to be useful in research, but much work
remains to establish the reproducibility and validity of
the spectroscopic profiles. Used with other proteomic
tools, it should serve as a valuable part of the proteo-
mic armamentarium for CSF studies.
Using another potentially useful approach, zymogra-
phy for matrix metalloproteinases, particularly MMP2,
and pMMP9 reportedly detect the presence of primary
and metastatic brain tumors [63]. Interestingly, leuko-
cyte counts were normal in these samples and MMP
was still an effective strategy with high sensitivity and
specificity. This is important because MMPs would be
expected to accompany leukocytosis and inflammation,
but their independent increase suggests that their role
in angiogenesis or another process is responsible for
their elevation.
Finally, trying to detect the fewest number of cells
possible leads to a need either to improve sensitivity
directly through more powerful targeting systems or to
enrich target population of cells. While RT-PCR is one
approach for amplifying rare molecules, another method
that deserves some consideration for increasing the cell
number is through culture of the CSF samples. While it
may prove impossible to meet with routine success with
this method, any successful cultures derived from CSF
could help answer important questions about metastatic
behavior. To date, only a few cases of successful isola-
tion of cell lines have been documented, and their prop-
erties have not been examined through the lens of
understanding the process of CSF metastasis [64,65].
Although these studies were not related directly to diag-
nostic use, they demonstrate that cells can be cultured
from the CSF, at least in certain cases. Now that techni-
ques have been established to isolate cancer progenitor
cells from larger populations of cancer cells derived
from gliomas, culturing these samples is especially
important to answer questions about the diagnostic and
prognostic value of these cells and their characteristics
[66]. If methods to culture neoplastic cells from patient
CSF could ever be refined to the point where growth
was reasonably common, the growth properties of the
cells in vitro could have useful prognostic implications.
In vivo detection
For all their advantages, all in vitro approaches suffer from
the collection limitations mentioned above. To be able to
examine the entire CSF pool, in vivo methods are neces-
sary (possibly with multiple access points in the event of
an obstruction of flow due to solid tumor or other changes
in the CNS anatomy). Therefore, multiple modalities of in
vivo CSF screening for cancer are under development.
Magnetic iron oxide nanoparticles (MIONs)
Iron oxide, is a potentially useful targeted imaging agent
because of its ability to function as a T2 contrast agent
for MRI [67]. In cell culture, magnetic iron oxide nano-
particles (MIONs) have been demonstrated to specifically
alter T2 properties of melanoma and breast cancer cells
when conjugated to 9.2.27 and HER2, respectively [68].
Furthermore, MIONs have been successfully combined
with quantum dots to allow for multimodal imaging [69].
Quantum Dots
The desirable luminescent properties of quantum dots
have led to multiple investigations of their in vivo appli-
cations. In animal models, quantum dots have been suc-
cessfully targeted to a variety of tumors [26]. The
critical concern for human use, however, is that the
most common quantum dot materials are toxic and
t h e ya r en o tk n o w nt ob es a f e l ye l i m i n a t e df r o mt h e
body [21]. Recently, silicon-based quantum dots have
been engineered and successfully used in vivo as part of
multimodal diagnostic and therapeutic agents targeted
to tumors with antibodies and peptide ligands. To create
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leagues combined quantum dots with magnetic iron
oxide nanoparticles and packed the combination into
micelles for in vivo delivery. Combining both particles
in one platform allowed for both optical and magnetic
resonance imaging using targeted agents [70].
Conclusions
As therapies for extra-neural cancers become more suc-
cessful, the CNS in general and the CSF in particular
are increasingly becoming the most common sites of
disease recurrence [71-73]. Emerging cell tagging meth-
ods show much promise for in vitro assessments and
in vivo surveillance, although further studies must be
done to establish their true clinical potential. In addition
to the methods under investigation, the literature
appears to lack any published efforts in some other
potentially useful techniques, including multiplexed
cytokine analysis, which has been useful in neurodegen-
erative diseases such as ALS, and magnetic resonance
spectroscopy, which is a common method of assessing
neural biomarkers noninvasively [74,75].
The ultimate goal of diagnostics in CSF is to detect
the earliest meaningful sign of neoplastic presence in
the CSF to enable clinicians to react with the most rele-
vant therapy. Currently, three key methods exist that are
fairly specific but lack the sensitivity early in the disease
course that will enable the most timely therapeutic
response. Future therapies must overcome the chal-
lenges of detecting few cells in a comparatively large
space either directly or by profiling soluble biomarkers
that herald their arrival. In the past decade, advances in
clinical imaging and targeting ligand development have
improved our ability to detect leptomeningeal involve-
ment. Based on the state of the field, flow cytometry
appears the most promising among the emerging tech-
nologies detailed here, particularly for aiding in the diag-
nosis of hematologic malignancies. Profiling of the
soluble markers of the CSF is likely to become impor-
tant in the future, but it is too early to say which
method will prove most reliable in attaining that end.
With the CSF more clinically relevant than ever,
methods for surveillance are becoming increasingly
important [2]. The effective management of cancer in
the CSF will begin with the development of more sensi-
tive diagnostic tools. With focused honing of these tech-
niques, the clinical armamentarium will expand and
empower clinicians to relieve patients of debilitating
neurological symptoms and deadly disease progression
with fewer delays and greater confidence.
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